Biopharma, a biopharmaceutical company based in Kyiv, will build production facilities to process 3.5 million liters of plasma in 10 years, the company’s president Konstantin Efimenko said.
“In 10 years, we have to build facilities capable of processing 3.5 million liters of plasma to meet the needs of Ukraine, the Balkans, Turkey, and the Middle East. We are working hard for this,” he said at the Kyiv International Economic Forum (KIEF) on Thursday.
Efimenko said that in March 2024, the company began building a plant in Uzhhorod.
“We are launching the plant in Uzhhorod in the first quarter of 2026, we have bought 3.5 hectares of land in the city of Arad, 200 km from Uzhhorod, in Romania, and we will start building the plant in March 2025,” he said.
Efymenko noted that in 2026, Biopharma plans to process 700 thousand liters of plasma at the plant in Bila Tserkva and reach a turnover of $250 million.
“We need to scale up. Our plant in Uzhhorod is two Bila Tserkva, our plant in Arania is two Bila Tserkva,” he said.
As reported, in early October, Efymenko said that the start of construction of the Biopharma plant (Biopharma, Kyiv) for the production of blood products in Romania would depend on the possibility of investment by companies from Ukraine. The cost of the project will be EUR 486 thousand.
In May 2025, the company plans to start installing equipment at the plant under construction in Uzhhorod, with commissioning to begin in April 2026.
Biopharma’s revenue in the first half of 2024 amounted to UAH 1.5 billion.
